Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products - PubMed (original) (raw)

Guideline

. 2004 Jun;289(1-2):1-16.

doi: 10.1016/j.jim.2004.06.002.

Yu Chen Barrett, Viswanath Devanarayan, Eugene Koren, Hank Liu, Mauricio Maia, Thomas Parish, George Scott, Gopi Shankar, Elizabeth Shores, Steven J Swanson, Gary Taniguchi, Daniel Wierda, Linda A Zuckerman

Affiliations

• PMID: 15251407
• DOI: 10.1016/j.jim.2004.06.002

Guideline

Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products

Anthony R Mire-Sluis et al. J Immunol Methods. 2004 Jun.

Abstract

Most biopharmaceutical therapeutics elicit some level of antibody response against the product. This antibody response can, in some cases, lead to potentially serious side effects and/or loss of efficacy. Therefore, the immunogenicity of therapeutic proteins is a concern for clinicians, manufacturers and regulatory agencies. In order to assess immunogenicity of these molecules, appropriate detection, quantitation and characterization of antibody responses are necessary. Inadequately designed antibody assays have led to the hampering of product development or, during licensure, post-marketing commitments. This document provides scientific recommendations based on the experience of the authors for the development of anti-product antibody immunoassays intended for preclinical or clinical studies. While the main focus of this document is assay design considerations, we provide scientific focus and background to the various assay performance parameters necessary for developing a valid assay. Sections on assay performance parameters, including those that appear in regulatory guidances, are contained in this manuscript.

PubMed Disclaimer

Similar articles

• Recommendations for the validation of immunoassays used for detection of host antibodies against biotechnology products.
  Shankar G, Devanarayan V, Amaravadi L, Barrett YC, Bowsher R, Finco-Kent D, Fiscella M, Gorovits B, Kirschner S, Moxness M, Parish T, Quarmby V, Smith H, Smith W, Zuckerman LA, Koren E. Shankar G, et al. J Pharm Biomed Anal. 2008 Dec 15;48(5):1267-81. doi: 10.1016/j.jpba.2008.09.020. Epub 2008 Sep 19. J Pharm Biomed Anal. 2008. PMID: 18993008 Review.
• Recommendations for the design, optimization, and qualification of cell-based assays used for the detection of neutralizing antibody responses elicited to biological therapeutics.
  Gupta S, Indelicato SR, Jethwa V, Kawabata T, Kelley M, Mire-Sluis AR, Richards SM, Rup B, Shores E, Swanson SJ, Wakshull E. Gupta S, et al. J Immunol Methods. 2007 Apr 10;321(1-2):1-18. doi: 10.1016/j.jim.2006.12.004. Epub 2007 Jan 12. J Immunol Methods. 2007. PMID: 17307199 Review.
• Recommendations on risk-based strategies for detection and characterization of antibodies against biotechnology products.
  Koren E, Smith HW, Shores E, Shankar G, Finco-Kent D, Rup B, Barrett YC, Devanarayan V, Gorovits B, Gupta S, Parish T, Quarmby V, Moxness M, Swanson SJ, Taniguchi G, Zuckerman LA, Stebbins CC, Mire-Sluis A. Koren E, et al. J Immunol Methods. 2008 Apr 20;333(1-2):1-9. doi: 10.1016/j.jim.2008.01.001. Epub 2008 Jan 29. J Immunol Methods. 2008. PMID: 18275969 Review.
• Comparison of competitive ligand-binding assay and bioassay formats for the measurement of neutralizing antibodies to protein therapeutics.
  Finco D, Baltrukonis D, Clements-Egan A, Delaria K, Gunn GR 3rd, Lowe J, Maia M, Wong T. Finco D, et al. J Pharm Biomed Anal. 2011 Jan 25;54(2):351-8. doi: 10.1016/j.jpba.2010.08.029. Epub 2010 Sep 21. J Pharm Biomed Anal. 2011. PMID: 20863644

Cited by

• Assessment of potential cross-reactivity of human endogenous matrix metalloproteinases with collagenase Clostridium histolyticum antibodies in human sera obtained from patients with Dupuytren's contracture.
  Edkins TJ, Koller-Eichhorn R, Alhadeff JA, Mayer U, Faust H, Del Tito BJ. Edkins TJ, et al. Clin Vaccine Immunol. 2012 Apr;19(4):562-9. doi: 10.1128/CVI.00018-12. Epub 2012 Feb 22. Clin Vaccine Immunol. 2012. PMID: 22357647 Free PMC article.
• The FDA's New Guideline "Generally Accepted Scientific Knowledge" (GASK): An Opportunity to Expedite the Approval of Biosimilars.
  Niazi SK. Niazi SK. Pharmaceuticals (Basel). 2023 Oct 25;16(11):1517. doi: 10.3390/ph16111517. Pharmaceuticals (Basel). 2023. PMID: 38004383 Free PMC article. Review.
• The efficacy and safety of insulin degludec given in variable once-daily dosing intervals compared with insulin glargine and insulin degludec dosed at the same time daily: a 26-week, randomized, open-label, parallel-group, treat-to-target trial in individuals with type 2 diabetes.
  Meneghini L, Atkin SL, Gough SC, Raz I, Blonde L, Shestakova M, Bain S, Johansen T, Begtrup K, Birkeland KI; NN1250-3668 (BEGIN FLEX) Trial Investigators. Meneghini L, et al. Diabetes Care. 2013 Apr;36(4):858-64. doi: 10.2337/dc12-1668. Epub 2013 Jan 22. Diabetes Care. 2013. PMID: 23340894 Free PMC article. Clinical Trial.
• Assessing the Immunogenicity of Biopharmaceuticals.
  Pineda C, Castañeda Hernández G, Jacobs IA, Alvarez DF, Carini C. Pineda C, et al. BioDrugs. 2016 Jun;30(3):195-206. doi: 10.1007/s40259-016-0174-5. BioDrugs. 2016. PMID: 27097915 Free PMC article. Review.
• A placebo-controlled, double-blind, dose-escalation study to assess the safety, tolerability and pharmacokinetics/pharmacodynamics of single and multiple intravenous infusions of AZD9773 in patients with severe sepsis and septic shock.
  Morris PE, Zeno B, Bernard AC, Huang X, Das S, Edeki T, Simonson SG, Bernard GR. Morris PE, et al. Crit Care. 2012 Feb 17;16(1):R31. doi: 10.1186/cc11203. Crit Care. 2012. PMID: 22340283 Free PMC article. Clinical Trial.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Elsevier Science

• Other Literature Sources

  • The Lens - Patent Citations Database